Daniel J. George, MD

Medical Oncologist, Director of GU Oncology Duke Cancer Institute

Dr Daniel George is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. He is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 150 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. Dr. George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC registry in advanced renal cell carcinoma and Co-PI of IRONMAN, an international, multi-sponsor supported registry in advanced prostate cancer. Dr. George serves on the ASCO scientific committee for non-prostate cancer, the Alliance GU scientific committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research and Clinical Advances in Hematology and Oncology.

Session Appearances

Neal D. Shore, MD, FACS

Medical Director

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, Society of Urologic Oncology Clinical Trials Consortium, Secretary-Treasurer, and is President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 125 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.

A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.